---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-011053"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:21:28.366558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix Q2 net loss $28.3M; cash $125.3M; FDA PDUFA Aug 15 for TNX-102 SL

## Summary
- Net product revenue $2.0M (down from $2.2M YoY); SG&A surged to $16.2M from $7.5M on pre-launch spend.
- Cash $125.3M at June 30; plus $51.5M raised in Q3 2025; runway into Q3 2026.
- FDA PDUFA date Aug 15, 2025 for TNX-102 SL (fibromyalgia); Fast Track designation.
- First patient dosed in DoD-funded OASIS trial of TNX-102 SL for acute stress reaction.
- Appointed Joseph Hand as General Counsel and James Hunter to board; added to Russell 2000/3000.

## SEC filing metadata
- accession: 0001999371-25-011053
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/0001999371-25-011053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/tnxp-8k_081125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-011053
- JSON: https://secwatch.observer/filing/0001999371-25-011053.json
- Plain text: https://secwatch.observer/filing/0001999371-25-011053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.